According to the report, “TCS’ broad portfolio; the company’s end-to-end R&D IT and business services capabilities, including strategic consulting and cloud-based, platform-based solutions; its vast geographic footprint; and its years of experience in the life science industry, all make TCS a formidable option for companies seeking a preferred vendor to address their R&D ITO needs.”
It goes on to say that “TCS is focusing on an advisory-led transformation approach for higher digital adoption and value creation with a focus on IP-based digital health, real-world evidence, scientific collaboration, connected smart labs, data-driven development, digital clinical trials, automation, and regulatory intelligence.”
“We leverage our deep contextual knowledge of the life sciences R&D value chain, cutting-edge R&D IT capabilities, investments in innovation around genomics and drug development, and expertise in AI / cognitive computing to help customers accelerate and scale up R&D programs which are core to their growth and transformation journeys,” said Vikram Karakoti, Global Co-Head, Life Sciences, TCS.
“This leadership position is a reflection of our strong vision, sustained investments in relevant capabilities, innovation efforts and the resultant market success.”
TCS partners with leading life sciences companies to drive innovation and reimagine their R&D processes by leveraging next generation platforms and emerging technologies. The company offers a full set of services spanning consulting, cognitive business operations and digital transformation services, as well as platform solutions in the life sciences sector.
Tata Consultancy Services Ltd ended at Rs3,833.70 per piece up by Rs62.6 or 1.66% from its previous closing of Rs3,771.10 per piece on the BSE.